Mineralys Therapeutics, Inc. MLYS Shares Reserved for Future Issuance Under Stock Plans
Shares Reserved for Future Issuance Under Stock Plans at other companies
Other financials
Where this comes from
Reported directly by Mineralys Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CommonStockCapitalSharesReservedForFutureIssuance.
The official record: Mineralys Therapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Mineralys Therapeutics, Inc.'s shares reserved for future issuance under stock plans.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Mineralys Therapeutics, Inc.'s shares reserved for future issuance under stock plans?
- Mineralys Therapeutics, Inc. (MLYS) reported shares reserved for future issuance under stock plans of 14.1M in Q1 2026.
- How has Mineralys Therapeutics, Inc.'s shares reserved for future issuance under stock plans changed year-over-year?
- Mineralys Therapeutics, Inc.'s shares reserved for future issuance under stock plans increased by 20.5% year-over-year, from 11.7M to 14.1M.
- What is the long-term trend for Mineralys Therapeutics, Inc.'s shares reserved for future issuance under stock plans?
- Over 2 years (2023 to 2025), Mineralys Therapeutics, Inc.'s shares reserved for future issuance under stock plans has grown at a 30.3% compound annual growth rate (CAGR), from 6.1M to 10.4M.
- What does shares reserved for future issuance under stock plans mean?
- This represents the total number of common shares authorized and set aside for future issuance to employees and directors under equity compensation plans. It provides insight into the potential future dilution of existing shareholders. Investors monitor this to assess the firm's long-term incentive structure.